Exact Sciences Corporation (EXAS)
-NasdaqCM 10.54 
0.04(0.38%) 4:00PM EDT
| Prev Close: | 10.58 |
|---|
| Open: | N/A |
|---|
| Bid: | 10.06 x 100 |
|---|
| Ask: | 10.74 x 1000 |
|---|
| 1y Target Est: | 12.89 |
|---|
| Beta: | 1.39 |
|---|
| Next Earnings Date: | N/A |
|---|
| Day's Range: | 10.31 - 10.69 |
|---|
| 52wk Range: | 6.93 - 12.30 |
|---|
| Volume: | 600,858 |
|---|
| Avg Vol (3m): | 1,445,070 |
|---|
| Market Cap: | 675.56M |
|---|
| P/E (ttm): | N/A |
|---|
| EPS (ttm): | -0.86 |
|---|
| Div & Yield: | N/A (N/A) |
|---|
The broker you select will become the default broker for Trade Now
Quotes delayed, except where indicated otherwise. Currency in USD.
Headlines
- 6 Ways You Can Profit From Molecular Diagnosticsat Seeking Alpha(Wed, May 22)
- Exact Sciences Corporation Presents at UBS Global Healthcare Conference, May-21-2013 10:30 AMat Seeking Alpha(Tue, May 21)
- A Game-Changing Cancer Screen For Exact Sciencesat Seeking Alpha(Tue, May 21)
- EXACT Sciences (EXAS) Shares Cross Above 200 DMAat TheStreet(Tue, May 14)
- EXACT SCIENCES CORP FinancialsEDGAR Online Financials(Fri, May 10)
- Why Exact Sciences Is Poised to Underperformat Motley Fool(Fri, May 3)
- Exact Sciences to Participate in May Investor ConferencesBusiness Wire(Fri, May 3)
- EXACT SCIENCES CORP Files SEC form 8-K, Change in Directors or Principal OfficersEDGAR Online(Fri, May 3)
- EXACT SCIENCES CORP Files SEC form 10-Q, Quarterly ReportEDGAR Online(Fri, May 3)
- Exact Sciences Management Discusses Q1 2013 Results - Earnings Call Transcriptat Seeking Alpha(Wed, May 1)
- A Cautious Outlook on the Cell Therapy Space: Expert Analyst Boris Peaker Interviews with The Wall Street Transcript and Discusses Challenges in Bringing Patients to Clinical StudiesWall Street Transcript(Wed, May 1)
- Exact Sciences Earnings: Here’s Why Investors are Not Happy Nowat Wall St. Cheat Sheet(Wed, May 1)
- Exact Sciences Reports First-Quarter 2013 Financial Results, Announces Addition to Board of DirectorsBusiness Wire(Wed, May 1)
- Q1 2013 EXACT Sciences Corporation Earnings Release - Before Market OpenCCBN(Wed, May 1)
- Brian Skorney, Senior Analyst at Robert W. Baird & Co., Interviews with The Wall Street Transcript: FDA Approvals Accelerate and Opportunities Arise in Hepatitis C MarketWall Street Transcript(Mon, Apr 29)
Key Statistics
| Forward P/E (1 yr): | N/A |
|---|
| P/S (ttm): | 163.64 |
|---|
| Ex-Dividend Date: | N/A |
|---|
Analysts
| Annual EPS Est
(Dec-13)
: | -0.76 |
|---|
| Quarterly EPS Est
(Jun-13)
: | -0.18 |
|---|
| Mean Recommendation*: | 2.0 |
|---|
| PEG Ratio (5 yr expected): | -0.77 |
|---|
Business Summary
Exact Sciences Corporation, a molecular diagnostics company, focuses on developing diagnostic screening products for the early detection and prevention of colorectal pre-cancer and cancer.
View More